There is limited evidence to support most off-label use of atypical antipsychotics, according to a review of the evidence by the Agency for Healthcare Research and Quality (AHRQ).
Increasing off-label use of atypical antipsychotics and requests for information about such use led the AHRQ to review the data to date (http://tinyurl.com/9am42ag). Medications of this class of drugs are approved by the US Food and Drug Administration for the treatment of schizophrenia and bipolar disorder, and a few have also been approved for major depression and autism-related aggression. Yet they are often prescribed for other indications.
Kuehn BM. Off-label Atypical Antipsychotics. JAMA. 2012;308(12):1198. doi:10.1001/2012.jama.12018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: